Ortho Clinical Diagnostics, Raritan, NJ, has received the CE mark for its Vitros XT 7600 integrated system. By combining proprietary dry slide technology with sophisticated digital imaging capabilities and the potential to perform two separate lab tests simultaneously, Ortho introduces digital chemistry to clinical lab management. Digital chemistry brings powerful data intelligence, operational improvements, and heightened quality to the lab to help clinical laboratories keep pace with a rapidly evolving global healthcare environment, without requiring additional lab space.
“Ortho’s Vitros XT 7600 harnesses the power of our proprietary dry slide technology to deliver even more enhanced, high-quality test results, higher throughput, and an improved patient experience, all within the lab’s existing physical footprint,” says Robert Yates, COO of Ortho Clinical Diagnostics. “It’s a fundamental change to the way labs operate.”
The digital chemistry behind Ortho’s Vitros XT 7600 uses three enabling technologies: dry slide, microslide, and digital imaging. Unlike traditional wet chemistry systems, which require highly purified water and complex plumbing systems, Ortho’s proprietary dry slide technology does not require water to run. This eliminates the risk that poor water quality could impact test results. MicroSlide technology is a full testing environment on a postage stamp-sized piece of film to facilitate precise and accurate testing in a waterless environment. With digital imaging, advanced optics glean significantly more information from testing than has been possible to date, enabling better precision and powerful data intelligence functions in the lab.
In addition, the instrument increases productivity, requiring less patient blood sample and introducing multitest processing, with the potential to offer two tests per slide instead of one. With XT MicroSlides, the Vitros system can pair tests that are frequently ordered for the same patient so they can be run simultaneously. This saves time and space in the lab and reduces the amount of blood needed for testing, an important advantage for vulnerable patients or those with venous access issues.
“We are an internationally renowned laboratory where quality comes first. The Ortho technology is stable and filters out most common interferences to deliver a high first-pass yield and minimal reruns,” says Phil Craddock-Jones, lab manager at Sheffield Children’s Hospital in the United Kingdom. “Ortho’s Vitros systems don’t require water to run, which reduces the risk of water contamination.”
The CE mark signifies conformance to applicable European Union regulatory requirements, and the Vitros system is now available for purchase in numerous countries in Africa, Asia, Europe, Latin America, and the Middle East. According to an Ortho spokesperson, the company intends to submit the instrument for FDA premarket clearance soon.
The Vitros chemistry, immunodiagnostics, and integrated systems comprise a portfolio of products and patented enabling technologies that help clinical laboratories diagnose, monitor, and treat disease. Vitros products are engineered to help clinical laboratories with organizational, operational, and economic challenges.
To learn more, visit Ortho Clinical Diagnostics.